Ki-67 Proliferative Index Predicts Response to Chemotherapy and Survival in 252 Patients with High-Grade Gastrointestinal Neuroendocrine Carcinoma (WHO G3)

Halfdan Sorbye1; Staffan Welin2; Seppo Langer3; Lena Vestermark4; Nanna Holt5; Pia Osterlund6; Svein, Dueland7; Eva Hofsl8; Marianne Guren9; Katarina Ohrling10; Elke Birkemeyer11; Espen Thiis-Evensen12; Matteo Biagini13; Henning Gronbaek14; Leena-Maija Soveri6; Ingrid Holst Olsen15; Birgitte Federspiel16; Jurg Assmus17; Eva Tiensuu Janson7; Ulrich Knigge15

1Department of Oncology, Haukeland University Hospital, Bergen, Norway.  
2Department of Medical Sciences, Uppsala University, Uppsala, Sweden  
3Department of Oncology, Rigshospitalet, University of Copenhagen, Denmark  
4Department of Oncology, Odense University Hospital, Denmark  
5Department of Oncology and Medical V, Aarhus University Hospital, Denmark  
6Department of Oncology, Helsinki University Central Hospital, Finland  
7Department of Oncology, Radium Hospital, Oslo University Hospital, Norway  
8Department of Oncology, St Olavs Hospital, University of Trondheim, Norway  
9Department of Oncology, Ullevål Hospital, Oslo University Hospital, Norway  
10Department of Oncology, Karolinska University Hospital, Stockholm, Sweden  
11Department of Oncology, Stavanger University Hospital, Stavanger, Norway  
12Department of Medicin, Oslo University Hospital, Rikshospitalet, Norway  
13Department of Pathology, Odense University Hospital, Denmark  
14Department of Medical V, Aarhus University Hospital, Denmark  
15Depart.of Surgery C, Rigshospitalet, University of Copenhagen, Denmark  
16Depart. of Pathology, Rigshospitalet, University of Copenhagen, Denmark  
17Center for Clinical Research, Haukeland University Hospital, Bergen, Norway

Background: Gastrointestinal neuroendocrine carcinoma (GI-NEC) are aggressive tumors and usually metastatic at diagnosis. GI-NEC have a high proliferation rate with a Ki-67 index >20% by definition, but it is often higher (>75%). Treatment of patients with gastrointestinal neuroendocrine carcinoma remains a challenge for the clinician, as published data are very limited on this subgroup of neuroendocrine tumors. We retrospectively reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients.

Methods: Epidemiological, biochemical, histopathological, treatment and survival data were registered for advanced GI-NEC patients treated with chemotherapy during 2000-2009 at 12 Nordic university hospitals.

Results: 252 patients were included. Response rate to 1st-line chemotherapy was 31%, 33% had stable disease, and median survival was 11 months. Ki-67<55% was by ROC analysis the best cut-off value concerning correlation to response rate. Response rate to 1st-line platinum-based chemotherapy was lower in patients with Ki-67<55% (14% vs. 44%, p<0.001). Response rate for 84 patients given 2nd-line chemotherapy was 18%, whereas 33% achieved SD. The most important negative prognostic factors for survival were poor performance status, primary colorectal tumors, and elevated platelets or lactate dehydrogenase (LDH) levels at baseline. Survival and response rates did not differ between the different platinum
chemotherapy schedules (cisplatin-based vs. carboplatin-based) or morphological subtypes. Patients with Ki-67<55% had longer median survival (15 months) than patients with Ki-67≥55% (10 months) (p<0.001).

**Conclusions:** GI-NEC patients with Ki-67<55% had significantly longer survival than patients with higher Ki-67, but were much less responsive to platinum-based chemotherapy. Platinum-based chemotherapy may not be the optimal chemotherapy schedule when Ki-67<55%. Our data indicate that it might not be correct to consider all GI-NEC as one single disease entity (WHO G3) as in the present WHO classification.